Simvastatin reduces endothelial NOS: caveolin-1 ratio but not the phosphorylation status of eNOS in vivo

J Atheroscler Thromb. 2012;19(8):705-11. Epub 2012 Jul 27.

Abstract

In vivo evidence for the pleiotropic effects of simvastatin on the nitric oxide synthase system is limited.

Aims: To determine if simvastatin can affect the endothelial nitric oxide synthase cascade.

Methods: New Zealand white rabbits (n=15) were divided: Group 1 (control) was fed a normal rabbit diet; Group 2 (MC) received a normal rabbit diet with 1% methionine (M) plus 0.5% cholesterol (C) and 5% peanut oil (atherogenic diet); Group 3 received the same diet as the MC group plus 5 mg/kg/ day simvastatin (S) orally (MCS). After 4 weeks, the abdominal aorta was collected and analyzed.

Results: Total cholesterol (TC) and total homocysteine (tHcy) were not significantly different between MCS and MC. Endothelial function was only reduced in MC (p<0.05). Although eNOS significantly increased in MC and MCS (p<0.01), simvastatin treatment significantly reduced endothelial caveolin-1 by 35% (p=0.038), causing a 2.5-fold (p=0.026) increase in the eNOS: caveolin-1 ratio. The phosphorylation of eNOS at the threonine 495 site or serine 1177 site was not affected by diet or treatment; however, a positive correlation between the two phosphorylation sites was observed (r(2)= 0.5, p=0.01).

Conclusion: in vivo pleiotropic effects of statin therapy include decreasing endothelial caveolin-1. Other therapies designed to affect eNOS phosphorylation in vivo might be useful in further preventing CVD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta, Abdominal / cytology
  • Aorta, Abdominal / drug effects*
  • Aorta, Abdominal / metabolism
  • Caveolin 1 / metabolism*
  • Cells, Cultured
  • Cholesterol / metabolism
  • Diet, Atherogenic*
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / enzymology*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Immunoenzyme Techniques
  • Male
  • Nitric Oxide Synthase Type III / metabolism*
  • Rabbits
  • Simvastatin / pharmacology*

Substances

  • Caveolin 1
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Cholesterol
  • Simvastatin
  • Nitric Oxide Synthase Type III